Wockhardt and Serum Life Sciences UK partner to manufacture multiple vaccines in UK

The facility will produce 150 million vaccine doses per year

Wockhardt’s novel antibiotic Phase 1 trial to be conducted by NIH, USA

The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process

Wockhardt Hospitals, Mira Road opens centre for sports medicine

The facility is spread across 215000 sq. feet and provides super-speciality care

Wockhardt gets CDSCO nod to export 100 million doses of Sputnik vaccines

Wockhardt has entered into an agreement with Russian Direct Investment Fund and Enso Healthcare to manufacture and supply Sputnik V and Sputnik Light vaccines against Covid-19

Wockhardt PAT at Rs 33.53 cr. in Q2FY22

The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.

Wockhardt and Jemincare partner for novel respiratory antibiotic Nafithromycin

The company to receive upfront and milestone payments, in addition to royalties

Wockhardt to manufacture and supply Sputnik V

Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19

NIFTY Pharma remains resilient amid mixed market sentiment

Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures

Karunanithi Ponnusamy elevated to President – Animal Health Business at Alembic Pharma

With over 30 years of pharmaceutical industry experience, Ponnusamy will lead Alembic’s animal health business strategy, market expansion, and operational growth initiatives

The Lancet Regional Health publishes pivotal phase 3 clinical study on Miqnaf